TREAT注册工作组共识:特应性皮炎治疗研究注册中心核心数据集的测量内容与时机
该共识针对中重度特应性皮炎(AE)光疗和系统治疗的真实世界长期证据有限、结局测量异质性高的问题,基于HOME倡议、TREATgermany数据库、系统综述和专家意见,通过三轮面对面会议、一次电话会议及邮件讨论,就核心数据集各域条目的测量工具和随访频率达成国际共识,旨在促进多中心数据可比与合并。
要点
- 共识明确了AE研究注册中心各核心域条目的测量工具。
- 随访频率:治疗开始后初始4周,治疗期间每3个月,停药期间每6个月。
- 标准化数据收集有助于跨国数据合并与长期疗效安全性评估。
核心结论
- 国际共识确定了AE研究注册中心核心数据集各域条目的测量工具与最低随访频率。
研究设计与样本
- 共识制定基于HOME倡议推荐、TREATgermany现有AE数据库、系统综述及专家意见,经三次面对面共识会议、一次电话会议和邮件讨论形成提案。
- 16名来自7个国家的专家参与「如何测量」共识过程,并咨询了12名外部专家。
- 随访频率由专家调查确定。
主要发现
- 对所有域条目就如何测量达成共识,并分配了测量工具。
- 确定最低随访频率为治疗开始后初始4周,治疗期间每3个月,停药期间每6个月。
关键数值与推荐
- 最低随访频率:治疗开始后初始4周,随后治疗期间每3个月,停药期间每6个月。
临床怎么用
- 该核心数据集可供各国AE研究注册中心使用,以收集统一数据。
- 标准化数据收集有助于跨国直接比较和数据合并,尤其适用于需大样本量的治疗相关不良事件分析。
- 收集的数据有助于深入了解AE光疗和系统治疗的长期疗效与安全性,为临床实践提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited. Such data must come from well-designed prospective patient registries. Standardization of data collection is needed for direct comparisons and data pooling. OBJECTIVES: To reach a consensus on how and when to measure the previously defined domain items of the TREatment of ATopic eczema (TREAT) Registry Taskforce core dataset for research registries for paediatric and adult patients with AE. METHODS: Proposals for the measurement instruments were based on recommendations of the Harmonising Outcome Measures for Eczema (HOME) initiative, the existing AE database of TREATgermany, systematic reviews of the literature and expert opinions. The proposals were discussed at three face-to-face consensus meetings, one teleconference and via e-mail. The frequency of follow-up visits was determined by an expert survey. RESULTS: A total of 16 experts from seven countries participated in the 'how to measure' consensus process and 12 external experts were consulted. A consensus was reached for all domain items on how they should be measured by assigning measurement instruments. A minimum follow-up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment was defined. CONCLUSIONS: This core dataset for national AE research registries will aid in the comparability and pooling of data across centres and country borders, and enables international collaboration to assess the long-term effectiveness and safety of phototherapy and systemic therapy used in patients with AE. What's already known about this topic? Comparable, real-life and long-term data on the effectiveness and safety of phototherapy and systemic therapy in patients with atopic eczema (AE) are needed. There is a high diversity of outcomes and instruments used in AE research, which require harmonization to enhance comparability and allow data pooling. What does this study add? Our taskforce has reached international consensus on how and when to measure core domain items for national AE research registries. This core dataset is now available for use by researchers worldwide and will aid in the collection of unified data. What are the clinical implications of this work? The data collected through this core dataset will help to gain better insights into the long-term effectiveness and safety of phototherapy and systemic therapy in AE and will provide important information for clinical practice. Standardization of such data collection at the national level will also allow direct data comparisons and pooling across country borders (e.g. in the analysis of treatment-related adverse events that require large patient numbers).
引用
- Vermeulen FM, Gerbens LAA, Bosma AL, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. Br J Dermatol. 2019. PMID: 30719709. doi:10.1111/bjd.17715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。